Phaseline

Companies › Sirius Therapeutics

Sirius Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Metabolic and endocrine, Cardiovascular; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SRSD107
siRNA-based anticoagulant
–Phase 2Venous Thromboembolism; Coronary Artery Disease (CAD)Dec 2027
SRSD216–Phase 1Hyperlipoproteinemia (a)Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07140523SRSD107Phase 2Venous ThromboembolismCardiovascularJun 2026
NCT07172646SRSD216Phase 1Hyperlipoproteinemia (a)Metabolic and endocrineApr 2027
NCT07318155SRSD107Phase 2Coronary Artery Disease (CAD)CardiovascularDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vincentage Pharma Shanghai Minwei Biotechnology HELP Therapeutics Crystalys Therapeutics Biomea Fusion

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.